Short communication: Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor in advanced brain tumor patients: Preliminary study

Hybridoma

Volumn 20, Issue 2, 2001, Pages 131-136

  Crombet, T ^a   Iznaga, N ^a   Perez R ^a   Lage, A ^a   Torres, O ^a   Rodriguez V ^a   Menendez A ^a   Stevenson, A ^a   Ramos, M ^a   Torres, F ^a   Figueredo, R ^a   Veitia I ^a  

^a CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY IOR EGF R3; TECHNETIUM; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT;

ADULT; ADVANCED CANCER; ANAPHYLACTIC SHOCK; ANTIBODY PRODUCTION; ARTICLE; ASTROCYTOMA; BRAIN TUMOR; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE COURSE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SENSITIZATION; FEMALE; FOLLOW UP; GLIOBLASTOMA; GLIOMA; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; MALE; MENINGIOMA; OLIGODENDROGLIOMA; PATIENT; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RECURRENT DISEASE; SCINTIGRAPHY; TOXICITY; TREATMENT OUTCOME; VISUAL DISORDER; ANIMAL; DOSE RESPONSE; IMMUNOLOGY; METABOLISM; MIDDLE AGED; MOUSE; SCINTISCANNING;

MURINAE;

ADULT; ANIMALS; ANTIBODIES, MONOCLONAL; ASTROCYTOMA; BRAIN NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MENINGIOMA; MICE; MIDDLE AGED; RADIOIMMUNODETECTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; TECHNETIUM; TREATMENT OUTCOME;

EID: 0034919864     PISSN: 0272457X     EISSN: None     Source Type: Journal    
DOI: 10.1089/02724570152057634     Document Type: Article

References (40)

1. Brain and other nervous system cancer. Trends in SEER incidence and U.S mortality
2. The new approaches to brain tumors. Cancer control
3. Signal transduction pathways and their relevance in human astrocytomas
4. Expression of epidermal growth factor receptors in human brain tumors
5. Expression of an altered epidermal growth factor receptor by human glioblastoma cells
6. Growth factors profiles of human gliomas. Do non-tumor cells contribute to tumor growth in glioma?
7. Expression of activated epidermal factor receptors, Ras-guanosine triphosphate, and mitogen activated protein kinase in human glioblastoma multiforme specimens
8. Inhibition of phospholipase C-gamma 1 activation blocks glioma cell motility and invasion of fetal rat brain aggregates
9. Establishing a link between oncogenes and tumor angiogenesis
10. Tumor angiogenesis: Past, present and near future
11. Generation and characterization of anti-EGFR antibodies
12. A new monoclonal antibody for detection of the EGF-R in Western blot and paraffin embedded tissue sections
13. Growth inhibition of human lung adenocarcinoma cells by antibodies against EGF-R and by ganglioside GM3
14. Oncogenes and tumor angiogenesis: The HPV-16 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner
15. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors
16. 99mTc labeled anti-human EGF-R in patients with tumours of epithelial origin. Clinical trial safety and diagnostic efficacy
17. Multiple infusions of anti-epidermal growth factor receptor (EGF-R) monoclonal antibody (EMD 55900) in patients with recurrent malignant gliomas
18. Harmonisation in pharmacovigilance
19. Statement of the clinical oncologic problem
20. Phenotype vs genotype in the evolution of astrocytic brain tumors
21. Genetic profile of gliosarcomas
22. Intralesional administration of iodine 131 in the treatment of malignant gliomas
23. Iodine 125 labeled anti epidermal growth factor receptor 425 in the treatment of malignant astrocytomas. A pilot study
24. Iodine 125 labeled anti epidermal growth factor receptor 425 in the treatment of glioblastoma multiforme. A pilot study
25. Malignant astrocytomas treated with iodine 125 labeled monoclonal antibody 425 against epidermal growth factor receptor: A phase II trial
26. Indium 111 labeled anti EGF-R 425 scintigraphy in the detection of malignant gliomas
27. Antibody guided irradiation of brain glioma by arterial infusion of radioactive monoclonal antibody against epidermal growth factor receptor and blood group A antigen
28. A phase I study of an anti-epidermal growth factor receptor monoclonal antibody for the treatment of malignant gliomas
29. The treatment of patients with recurrent malignant gliomas with intratumoral radioimmunoconjugates
30. Antibody guided diagnosis and therapy of brain gliomas using radiolabeled monoclonal antibodies against epidermal growth factor receptor and placental alkaline phosphatase
31. Utilization of 125 iodine monoclonal antibody in the management of primary glioblastoma multiforme
32. The use of epidermal growth factor receptor-425 monoclonal antibodies radiolabeled with iodine 125 in the adjuvant treatment of patients with high grade gliomas of the brain
33. Epidermal growth factor receptor 425 monoclonal antibodies radiolabeled with iodine125 in the adjuvant treatment of high grade astrocytomas
34. Intratumoral infusions of the monoclonal antibody, mAb 425, against the epidermal growth factor receptor in patients with advanced malignant gliomas
35. Clinical and pathological significance of p53 gene mutation in human cerebral glioblastoma multiforme
36. Prognostic significance of Ki67, p53, and EGFR immunostaining in human glioblastomas
37. Comparative analysis of proliferating cell nuclear antigen and epidermal growth factor receptor epression in glial tumours: Correlation with histological grading
38. Association of EGFR gene amplification and CDKN2 (p16/MTS1) gene deletion in glioblastoma multiforme
39. Restoration of wild type p16 downregulates vascular endothelial growth factor expression and inhibits angiogenesis in human gliomas
40. Humanization of a mouse monoclonal antibody that blocks the EGF-R: Recovery of antagonistic activity